What is lincomycin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lincomycin: Overview and Clinical Applications

Lincomycin is a lincosamide antibiotic produced by Streptomyces lincolnensis that is primarily active against gram-positive bacteria and anaerobes, but has largely been replaced by its more potent derivative clindamycin in modern clinical practice. 1, 2

Chemical Structure and Properties

  • Lincomycin hydrochloride is chemically known as Methyl 6,8-dideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrolidinecarboxamido)-1-thio-D-erythro-α-D-galacto-octopyranoside monohydrochloride monohydrate with a molecular formula of C18H34N2O6S·HCl·H2O 3
  • It appears as a white or practically white, crystalline powder that is freely soluble in water 3
  • Lincomycin is available as an injectable formulation containing 300 mg/mL of lincomycin (equivalent to 340 mg/mL of lincomycin hydrochloride) 3

Mechanism of Action

  • Lincomycin acts by binding to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis 1, 2
  • While primarily bacteriostatic, lincomycin may exhibit bactericidal effects at higher concentrations 2
  • It shares its mechanism of action with other lincosamides, particularly clindamycin, which is its chlorinated semi-synthetic derivative 2

Antimicrobial Spectrum

  • Effective primarily against gram-positive cocci including:
    • Staphylococci (including many hospital strains resistant to other antibiotics) 4
    • Streptococci (including group A and unclassifiable streptococci) 1
    • Pneumococci 1
  • Active against most anaerobic bacteria, including Bacteroides fragilis 1
  • Limited activity against gram-negative aerobic pathogens 1

Clinical Applications

  • Historically used for treatment of severe staphylococcal infections caused by resistant organisms 4
  • Demonstrated efficacy in dermatological infections such as:
    • Carbuncles, furuncles, and folliculitis 5
    • Cellulitis, lymphangitis, and lymphadenitis 5
    • Pyonychias and dermatitis infectiosa eczematoides 5
  • Has shown promising results in osteomyelitis cases 4
  • Has been used in some cases of acne conglobata (cystic acne) with encouraging results 5
  • In modern practice, clindamycin has largely replaced lincomycin due to superior activity, particularly against anaerobic infections 1, 2

Administration and Pharmacokinetics

  • Can be administered orally, intramuscularly, or intravenously 1
  • After oral administration, peak serum levels are reached within the first hour 1
  • Serum half-life ranges from 2 to 3.8 hours in healthy individuals 1
  • Diffuses well into most tissues but has poor penetration into the central nervous system and cerebrospinal fluid 1
  • Dosage adjustments are necessary in patients with severe renal or hepatic impairment 1

Adverse Effects and Precautions

  • Generally well-tolerated, but gastrointestinal side effects are common 1, 5
  • Loose stools and diarrhea frequently reported but typically resolve with dosage reduction 5
  • Risk of pseudomembranous colitis (Clostridioides difficile infection) is a significant concern 1
  • Due to limited activity against gram-negative pathogens, often requires combination with other antibiotics (typically aminoglycosides) for mixed infections 1

Resistance Mechanisms

  • Bacterial resistance to lincomycin can occur through:
    • Methylation of 23S ribosomal RNA 2
    • Enzymatic modification of the antibiotic 2
    • Active efflux from bacterial cells 2
  • Cross-resistance between lincomycin and clindamycin is common due to shared mechanisms of action 2

Current Status in Clinical Practice

  • Clindamycin has largely replaced lincomycin in modern clinical practice due to its enhanced antimicrobial activity 1, 2
  • For skin and soft tissue infections, newer agents like linezolid, daptomycin, and vancomycin are now preferred for resistant gram-positive infections 6
  • When treating anaerobic infections, clindamycin is typically preferred over lincomycin 1

Biosynthesis and Production

  • Produced by fermentation using Streptomyces lincolnensis var. lincolnensis 4, 7
  • Biosynthetic pathway and genetic control have been extensively studied 7
  • Commercial production involves cultivation of producing strains under optimized conditions 7

References

Research

[Lincosamides].

Pathologie-biologie, 1986

Research

LINCOMYCIN IN DERMATOLOGIC PRACTICE.

Canadian Medical Association journal, 1965

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lincomycin, cultivation of producing strains and biosynthesis.

Applied microbiology and biotechnology, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.